{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:45:27Z","timestamp":1783507527504,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.bbrc.2017.03.145","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T07:03:29Z","timestamp":1490684609000},"page":"985-991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and \u03b2klotho agonist antibodies"],"prefix":"10.1016","volume":"486","author":[{"given":"Ognjen","family":"Grujic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennitte","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Y.-T.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer V.","family":"Weiszmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sekirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Badh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Grauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Manchulenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Foltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2017.03.145_bib1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/imr.12409","article-title":"Discovery and bio-optimization of human antibody therapeutics using the XenoMouse(R) transgenic mouse platform","volume":"270","author":"Foltz","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bbrc.2017.03.145_bib2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2017.03.145_bib3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib5","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1161\/CIRCULATIONAHA.113.002033","article-title":"Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know","volume":"127","author":"Foltz","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.bbrc.2017.03.145_bib6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molimm.2015.03.255","article-title":"Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases","volume":"67","author":"Irani","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nri3582","article-title":"The function of Fcgamma receptors in dendritic cells and macrophages","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0161-5890(01)00050-5","article-title":"The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds","volume":"38","author":"Schuurman","year":"2001","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib10","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2017.03.145_bib11","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nbt1207-1369","article-title":"Isotype selection in antibody engineering","volume":"25","author":"Salfeld","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib12","doi-asserted-by":"publisher","first-page":"29266","DOI":"10.1074\/jbc.M804787200","article-title":"Human IgG2 antibody disulfide rearrangement in\u00a0vivo","volume":"283","author":"Liu","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2017.03.145_bib13","doi-asserted-by":"publisher","first-page":"16194","DOI":"10.1074\/jbc.M709987200","article-title":"Human IgG2 antibodies display disulfide-mediated structural isoforms","volume":"283","author":"Wypych","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2017.03.145_bib14","doi-asserted-by":"publisher","first-page":"16206","DOI":"10.1074\/jbc.M709988200","article-title":"Structural and functional characterization of disulfide isoforms of the human IgG2 subclass","volume":"283","author":"Dillon","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2017.03.145_bib15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.molimm.2012.12.005","article-title":"IgG2 disulfide isoform conversion kinetics","volume":"54","author":"Liu","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nrd2637","article-title":"Directing cancer cells to self-destruct with pro-apoptotic receptor agonists","volume":"7","author":"Ashkenazi","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2017.03.145_bib17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccr.2010.11.012","article-title":"An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells","volume":"19","author":"Wilson","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2017.03.145_bib18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccell.2014.11.001","article-title":"Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies","volume":"27","author":"White","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2017.03.145_bib19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4049\/jimmunol.176.1.191","article-title":"Regulation of myeloid cell function through the CD200 receptor","volume":"176","author":"Jenmalm","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib20","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.4049\/jimmunol.0901531","article-title":"Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells","volume":"183","author":"Mihrshahi","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib21","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.4049\/jimmunol.173.11.6786","article-title":"Molecular mechanisms of CD200 inhibition of mast cell activation","volume":"173","author":"Zhang","year":"2004","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2017.03.145_bib22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.drudis.2013.10.021","article-title":"Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome","volume":"19","author":"Zhang","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2017.03.145_bib23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004690","article-title":"Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho\/FGFR1c receptor complex","volume":"4","author":"Foltz","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2017.03.145_bib24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jchromb.2006.09.026","article-title":"Downstream processing of monoclonal antibodies\u2013application of platform approaches","volume":"848","author":"Shukla","year":"2007","journal-title":"J.\u00a0Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.bbrc.2017.03.145_bib25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/btpr.2021","article-title":"Uncovering methods for the prevention of protein aggregation and improvement of product quality in a transient expression system","volume":"31","author":"Estes","year":"2015","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.bbrc.2017.03.145_bib26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00262-013-1398-6","article-title":"FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs","volume":"62","author":"White","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbrc.2017.03.145_bib27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1747-0285.2012.01325.x","article-title":"Understanding the physical interactions in the FGF21\/FGFR\/beta-Klotho complex: structural requirements and implications in FGF21 signaling","volume":"79","author":"Yie","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bbrc.2017.03.145_bib28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0022-1759(99)00137-4","article-title":"Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies","volume":"231","author":"Green","year":"1999","journal-title":"J.\u00a0Immunol. Methods"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X17306216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X17306216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T05:25:07Z","timestamp":1535952307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X17306216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0006291X17306216"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.03.145","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and \u03b2klotho agonist antibodies","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.03.145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}